TriSalus Life Sciences, Inc. (NASDAQ:TLSI) CEO Acquires $26,156.92 in Stock

TriSalus Life Sciences, Inc. (NASDAQ:TLSI) CEO Mary T. Szela purchased 4,826 shares of the company’s stock in a transaction that occurred on Monday, January 27th. The shares were purchased at an average cost of $5.42 per share, for a total transaction of $26,156.92. Following the completion of the transaction, the chief executive officer now directly owns 429,503 shares of the company’s stock, valued at $2,327,906.26. This represents a 1.14 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website.

TriSalus Life Sciences Price Performance

NASDAQ TLSI traded down $0.04 on Wednesday, reaching $4.93. 16,469 shares of the company’s stock traded hands, compared to its average volume of 23,643. The stock has a market cap of $150.32 million, a PE ratio of -1.98 and a beta of 0.51. TriSalus Life Sciences, Inc. has a 12 month low of $3.50 and a 12 month high of $10.42. The stock has a 50-day simple moving average of $4.55 and a 200 day simple moving average of $4.75.

Analyst Ratings Changes

Several equities analysts have commented on TLSI shares. Northland Securities initiated coverage on shares of TriSalus Life Sciences in a research report on Friday, October 25th. They set an “outperform” rating and a $12.50 target price on the stock. Cantor Fitzgerald started coverage on TriSalus Life Sciences in a report on Tuesday, December 17th. They set an “overweight” rating and a $10.00 price target on the stock. Roth Mkm reiterated a “buy” rating and set a $11.00 target price on shares of TriSalus Life Sciences in a research note on Friday, January 24th. Canaccord Genuity Group reduced their price target on shares of TriSalus Life Sciences from $12.00 to $11.00 and set a “buy” rating for the company in a research report on Friday, November 15th. Finally, Roth Capital upgraded TriSalus Life Sciences to a “strong-buy” rating in a research note on Monday, November 11th. Seven research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, TriSalus Life Sciences currently has a consensus rating of “Buy” and a consensus price target of $11.79.

Institutional Trading of TriSalus Life Sciences

Institutional investors have recently modified their holdings of the company. Geode Capital Management LLC boosted its holdings in TriSalus Life Sciences by 45.4% in the third quarter. Geode Capital Management LLC now owns 200,427 shares of the company’s stock valued at $924,000 after acquiring an additional 62,542 shares in the last quarter. MSD Partners L.P. bought a new position in shares of TriSalus Life Sciences during the third quarter valued at approximately $184,000. Vestcor Inc bought a new position in TriSalus Life Sciences during the 3rd quarter valued at approximately $108,000. Virtu Financial LLC purchased a new position in shares of TriSalus Life Sciences in the 3rd quarter worth about $92,000. Finally, Walleye Capital LLC purchased a new position in TriSalus Life Sciences in the third quarter worth about $66,000. 2.58% of the stock is currently owned by hedge funds and other institutional investors.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.